Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma

PLoS ONE

Volumn 3, Issue 2, 2008, Pages

  Jiang, Yanjun ^a   Xu, Dongsheng ^a   Zhao, Yong ^b   Zhang, Luwen ^a,b  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b UNIVERSITY OF NEBRASKA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; HUMAN HERPESVIRUS 8 REPLICATION AND TRANSCRIPTION ACTIVATOR; IMMEDIATE EARLY PROTEIN BZLF1; LEUCINE ZIPPER PROTEIN; VIRUS PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE LOCATION; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; MIXED INFECTION; NONHUMAN; PATHOGENESIS; PRIMARY EFFUSION LYMPHOMA; TRANSACTIVATION; TRANSCRIPTION INITIATION; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REPLICATION; B CELL LYMPHOMA; CHEMISTRY; DRUG ANTAGONISM; PATHOGENICITY; PROTEIN BINDING; PROTEIN DOMAIN; VIROLOGY; VIRUS INFECTION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 8;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, PRIMARY EFFUSION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; TRANS-ACTIVATION (GENETICS); VIRAL PROTEINS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 45249104917     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001569     Document Type: Article

References (88)

1. Kieff E (1996) Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, eds. Virology, 3rd Edition. Philadelphia, PA: Lippinscott-Raven Publishers. pp 2343-2396.
2. Rickinson AB, Kieff E (1996) Epstein-Barr Virus. In: Fields BN, Knipe DM, Howley PM, eds. Virology, 3rd Edition. Philadelphia, PA: Lippinscott-Raven Publishers. pp 2397-2446.
3. Raab-Traub N (1996) Pathogenesis of Epstein-Barr virus and its associated malignancies. Semin Virol 7: 315-323.
4. Pagano JS (199 1) Epstein-Barr Virus. In: Kelley WN, ed. Textbook of Internal Medicine. 2nd ed. Philadelphia, PA:J. B. Lippincott Co. chapt 307: 1499-1503.
5. Pagano JS (1999) Epstein-Barr vinis: the first human tumor virus and its role in cancer. Proc Assoc Am Physicians 111: 573-580.
6. Moore P, Chang Y (2001) Kaposi's Sacrcoma-Associated Herpesvirus. In: Knipe DM, ed. Virology. Philadelphia: Lippincott Williams and Wilkins. pp 2803-2833.
7. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma, Science 266: 1865-1869.
8. Chang Y, Moore PS (1996) Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS. Infect Agents Dis 5: 215-222.
9. West JT, Wood C (2003) The role of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression. Oncogene 22: 5150-5163.
10. Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM (2003) Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpes-virus-B) epidemiology and pathogenesis. Microbiol Mol Biol Rev 67: 175-212, table of contents.
11. Sun R, Lin SF, Staskus K, Gradoville I, Grogan E, et al. (1999) Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 73: 2232-2242.
12. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F, et al. (1998) A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 95: 10866-10871.
13. Lukac DM, Kirshner JR, Ganem D (1999) Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol 73: 9348-9361.
14. Sakakibara S, Ueda K, Chen J, Okuno T, Yamanishi K (2001) Octamer-binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression. J Virol 75: 6894-6900.
15. Zhu FX, Cusano T, Yuan Y (1999) Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus. J Virol 73: 5556-5567.
16. Gradoville L, Gerlach J, Grogan E, Shedd D, Nikiforow S, et al. (2000) Kaposi's sarcoma-associated herpesvirus. open reading frame 50/Rta protein activates the entire vital lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol 74: 6207-6212.
17. Saveliev A, Zhu F, Yuan Y (2002) Transcription mapping and expression patterns of genes in the major immediate-early region of Kaposi's sarcoma-associated herpesvirus. Virology 299: 301-314.
18. Zhang J, Wang J, Wood C, Xu D, Zhang L (2005) Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 Replication and Transcription Activator Regulates Viral and Cellular Genes via Interferon-Stimulated Response Elements. J Virol 79: 5640-5652.
19. Wang S, Liu S, Wu MH, Geng Y, Wood C (2001) Identification of a cellular protein that interacts and synergizes with the RTA (ORF50) protein of Kaposi's sarcoma-associated herpesvirus in transcriptional activation. J Virol 75: 11961-11973.
20. Gwack Y, Byun H, Hwang S, Lim C, Choe J (2001) CREB-binding protein and histone deacetylase regulate the transcriptional activity of Kaposi's sarcoma-associated herpesvirus open reading frame 50. J Virol 75: 1909-1917.
21. Gwack Y, Hwang S, Lim C, Won YS, Lee CH, et al. (2002) Kaposi's Sarcoma-associated herpesvirus open reading frame 50 stimulates the transcriptional activity of STAT3. J Biol Chem 277: 6438-6442.
22. Liao W, Tang Y, Lin SF, Kung HJ, Giam CZ (2003) K-bZIP of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) binds KSHV/HHV-8 Rta and represses Rta-mediated transactivation. J Virol 77: 3809-3815.
23. Liang Y, Chang J, Lynch SJ, Lukac DM, Ganem D (2002) The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev 16: 1977-1989.
24. Liang Y, Ganem D (2003) Lytic but not latent infection by Kaposi's sarcoma-associated herpesvirus requires host CSL protein, the mediator of Notch signaling. Proc Natl Acad Sci U S A 100: 8490-8495.
25. Deng H, Chu JT, Rettig MB, Martinez-Maza O, Sun R (2002) Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpevirus up-regulates human interleukin-6 gene expression. Blood 100: 1919-1921.
26. Gwack Y, Hwang S, Byun H, Lim C, Kim JW, et al. (2001) Kaposi's sarcoma-associated herpesvirus open reading frame 50 represses p53-induced transcriptional activity and apoptosis. J Virol 75: 6245-6248.
27. Lan K, Kuppers DA, Verma SC, Sharma N, Murakami M, et al. (2005) Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency. J Virol 79: 7453-7465.
28. Matsumura S, Fujita Y, Gomez E, Tanese N, Wilson AC (2005) Activation of the Kaposi's sarcoma-associated herpesvirus major latency locus by the lytic switch protein RTA (ORF50). J Virol 79: 8493-8505.
29. Chang H, Gwack Y, Kingston D, Souvlis J, Liang Y, et al. (2005) Activation of CD21 and CD23 gene expression by Kaposi's sarcoma-associated herpesvirus RTA. J Virol 79: 4651-4663.
30. Chevallier GA, Manet E, Chavrier P, Mosnier C, Daillie J, et al. (1986) Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. Embo J 5: 3243-3249.
31. Countryman J, Miller G (1985) Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci USA 82: 4085-4089.
32. Kouzarides T, Packham G, Cook A, Farrell PJ (1991) The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene 6: 195-204.
33. Kenney S, Kamine J, Markovitz D, Fenrick R, Pagano J (1988) An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human inummodeficiency virus long terminal repeat. Proceedings of the National Academy of Sciences USA 85: 1652-1656.
34. Lieberman PM, Berk AJ (1990) In Vitro transcriptional activation, dimerization, and DNA-binding specificity of the Epstein-Barr virus Zta protein. J Virol 64: 2560-2568.
35. Lieberman PM, Berk AJ (1991) The Zta-trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes and Development 5: 2441-2454.
36. Lieberman PM, Hardwick JM, Sample J, Hayward GS (1990) The Zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J Virol 64: 1143-1155.
37. Manet E, Gruffat H, Trescol-Biemont MC, Moreno N, Chambard P, et al. (1989) Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional transactivators. European Molecular Biology Organization Journal 8: 1819-1826.
38. Feederle R; Kost M, Baumann M, Janz A, Drourt E, et al. (2000) The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. Embo J 19: 3080-3089.
39. Cayrol C, Flemington E (1996) G0/G1 growth arrest mediated by a region encompassing the basic leucine zipper (bZIP) domain of the Epstein-Barr virus transactivator Zta. J Biol Chem 271: 31799-31802.
40. Cayrol C, Flemington EK (1996) The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cyle arrest through induction of cyclin-dependent kinase inbibitors. Embo J 15: 2748-2759.
41. Adamson AL, Kenney S (2001) Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol 75:2388-2399.
42. Bell P, Lieberman PM, Maul GG (2000) Lytic but not latent replication of epstein-barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins. J Virol 74: 11800-11810.
43. Flemington E, Speck SH (1990) Autoregulation of Epstein-Barr virus BZLF1 putative lytic switch gene BZLF1. J Virol 64: 1227-1232.
44. Urier G, Buisson M, Chambard P, Sergeant A (1989) The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J 8: 1447-1453.
45. Deng H, Young A, Sun R (2000) Auto-activation of the rta gene of human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus. J Gen Virol 81: 3043-3048.
46. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ et al. (1996) Primary effusion lyrnphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88: 645-656.
47. Drexler HG, Uphoff CC, Gaidano G, Carbone A (1998) Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Leukemia 12: 1507-1517.
48. Trivedi P, Takazawa K, Zompetta C, Cuomo L, Anastasiadou E, et al. (2004) Infection of HHV-B+ primary effusion lymphoma, cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression. Blood 103: 313-316.
49. Fan W, Bubman D, Chadburn A, Harrington WJ Jr, Cesarman E, et al. (2005) Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol 79: 1244-1251.
50. Groves AV, Cotter MA, Subramanian C, Robertson ES (2001) The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr vinis latent promoters. J Virol 75: 9446-9457.
51. Krithivas A, Young DB, Liao G, Greene D, Hayward SD (2000) Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL celts. J Virol 74: 9637-9645.
52. Xu D, Coleman T, Zhang J, Fagot A, Kotalik C, et al. (2007) Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. J Virol 81: 6068-6078.
53. Miller G, Heston L, Grogan E, Gradoville L, Rigsby M, et al. (1997) Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol 71: 314-324.
54. Fujii K, Yokoyama N, Kiyono T, Kuyushima K, Homma M, et al. (2000) The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLFI-BBLF2/3 complex. J Virol 74: 2550-2557.
55. Fixman ED, Hayward GS, Hayward SD (1992) Trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. Journal of Virology 66: 5030-5039.
56. Tsurumi T, Kobayashi A, Tamai K, Daikoku T, Kurachi R, et al. (1993) Functional Expression and Characterization of the Epstein-Barr Virus DNA Polymerase Catalytic subunit J Virol 67: 4651-4658.
57. Tsurumi T, Daikoku T, Kurachi R, Nishiyama Y (1993) Functional Interaction between Epstein-Barr Virus DNA Polymerase Catalytic Subunit and Its Accessory Subunit In Vitro. J Virol 67: 7648-7653.
58. Tsurumi T, Daikoku T, Nishiyama Y (1994) Further Characterization of the Interaction between the Epstein-Barr Virus DNA Polymerase Catalytic Subunit and Its Accessory Subunit with Regard to the 3′-to-5′ Exonucleolytic Activity and Stability of Initiation Complex at Primer Terminus. J Virol 68: 3354-3363.
59. Zacny VL, Gershburg E, Davis MG, Biron KK, Pagano JS (1999) Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J Virol 73: 7271-7277.
60. Gershburg E, Pagano JS (2002) Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. J Virol 76: 998-1003.
61. Wang P, Day L, Dheekollu J, Lieberman PM (2005) A redox-sensitive cysteine in Zta is required for Epstein-Barr virus lytic cycle DNA replication. J Virol 79: 13298-13309.
62. Cox MA, Leahy J, Hardwick JM (1990) An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J Virol 64: 313-321.
63. Holley-Guthrie EA, Quinlivan EB, Mar EC, Kenney S (1990) The Epstein-Barr virus; (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol 64: 3753-3759.
64. Liu P, Speck SH (2003) Synergistic autoactivation of the Epstein-Barr virus immediate-early BRLF1 promoter by Rta and Zta. Virology 310: 199-206.
65. Wang SE, Wu FY, Fujimuro M, Zong J, Hayward SD, et al. (2003) Role of CCAAT/cnhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic-cycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP. J Virol 77: 600-623.
66. Izumiya Y, Lin SF, Ellison T, Chen LY, Izumiya C, et al. (2003) Kaposi's sarcoma-associated herpesvirus K-bZIP is a coregulator of K-Rta: physical association and promoter-dependent transcriptional repression. J Virol 77: 1441-1451.
67. Wu FY, Wang SE, Tang QQ, Fujimuro M, Chiou CJ, et al. (2003) Cell cycle arrest by Kaposi's sarcoma-associated herpesvirus replication-associated protein is mediated at both the transcriptional and posttranslational levels by binding to CCAAT/enhancer-binding protein alpha and p2l(CIP-1). J Virol 77: 8893-8914.
68. Zhang Q, Gutsch D, Kenney S (1994) Functional and physical interaction between p53 and BZLF1: Implications for Epstein-Barr virus latency. Mol Cell Biol 14: 1929-1938.
69. Hwang S, Gwack Y, Byun H, Lim C, Choe J (2001) The Kaposi's sarcoma-associated herpesvirus K8 protein interacts with CREB-binding protein (CBP) and represses CBP-mediated transcription. J Virol 75: 9509-9516.
70. Deng Z, Chen CJ, Zerby D, Delecluse HJ, Lieberman PM (2001) Identification of acidic and aromatic residues in the Zta activation domain essential for Epstein-Barr virus reactivation. J Virol 75: 10334-10347.
71. Park J, Seo T, Hwang S, Lee D, Gwack Y, et al. (2000) The K-bZIP protein from Kaposi's sarcoma-associated herpesvirus interacts with p53 and represses its transcriptional activity. J Virol 74: 11977-11982.
72. Zerby D, Chen CJ, Poon E, Lee D, Shickhattar R, et al. (1999) The amino-terminal C/H1 domain of CREB binding protein mediates zta transcriptional activation of latent Epstein-Barr virus. Mol Cell Biol 19: 1617-1626.
73. Wit FY, Tang QQ, Chen H, ApRhys C, Farrell C, et al. (2002) Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p2lCIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-alpha. Proc Natl Acad Sci U S A 99: 10683-10688.
74. Adamson AL, Kenney S (1999) Ile Epstein-Barr virus BZLF1 protein interacts physically and functionally with the historic acetylase CREB-binding protein. J Virol 73: 6551-6558.
75. Bu W, Carroll KD, Palmeri D, Lukac DM (2007) Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer. J Virol 81: 5788-5806.
76. Carroll KD, Bu W, Palmeri D, Spadavecchia S, Lynch SJ, et al. (2006) Kaposi's Sarcoma-associated herpesvirus lytic switch protein stimulates DNA binding of RBP-Jk/CSL to activate the Notch pathway. J Virol 80: 9697-9709.
77. Wang SE, Wu FY, Yu Y, Hayward GS (2003) CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters. J Virol 77: 9590-9612.
78. Flemington E, Speck SH (1990) Evidence of coiled-coil dimer formation by an Epstein-Barr virus transactivator that lacks a heptad repeat of leucine residues. Proc Natl Acad Sci USA 87: 9459-9463.
79. Sinclair AJ (2003) hZIP proteins of human gammaherpesviruses. J Gen Virol 84: 1941-1949.
80. Ye J, Gradoville L, Daigle D, Miller G (2007) De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists. J Virol 81: 9279-9291.
81. Cesarman E, Moore PS, Rao PH, Inghirami G, Knowles DM, et al. (1995) In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86: 2708-2714.
82. Arvanitakis L, Mesri EA, Nador RG, Said JW, Asch AS, et al. (1996) Establishment and characterization of a primary effusion (body cavity-based) lymphoma, cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88: 2648-2634.
83. Borza CM, Hutt-Fletcher LM (2002) Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 8: 594-599.
84. Seaman WT, Ye D, Wang RX, Hale EE, Weisse M, et al. (1999) Gene expression from the ORF50/K8 region of Kaposi's sarcoma-associated herpesvirus. Virology 263: 436-449.
85. Zhang L, Pagano JS (2001) Interferon Regulatory factor 7 mediates the activation of Tap-2 by Epstein-Barr virus latent membrane protein 1. J Virol 75: 341-350.
86. Zhang L Wu LH, Hong K, Pagano JS (2001) Intracellular signaling molecules activated by Epstein Barr virus for induction of interferon regulatory factor 7. J Virol 75: 12393-12401.
87. Zhang L, Pagano JS (2000) Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1. J Virol 74: 5748-5757.
88. Zhang L, Pagano JS (1999) Interferon Regulatory Factor 2 Represses the Epstein-Barr Virus BamH I Q Latency Promoter In Type III Latency. Mol Cell Biol 19: 3216-3223.